Core Insights - Veeva Systems has launched SiteVault, a Clinical Trial Management System (CTMS) aimed at research sites, integrating with SiteVault eISF and SiteVault eConsent for streamlined clinical trial management [1][4][10] - The new system addresses the need for efficient and scalable solutions in clinical trial management, offering a centralized platform that enhances coordination and compliance [2][4] - Following the announcement, Veeva's stock experienced a decline of 1.6%, closing at $227.90, although it has seen a 9.8% increase over the past six months [3][5] Company Developments - SiteVault CTMS is designed to consolidate essential trial processes, reducing administrative burdens and ensuring regulatory compliance [7][9] - The integration with Veeva's Clinical Platform allows for bidirectional data flow, improving trial oversight and reducing manual data entry [8] - The anticipated release of SiteVault CTMS is set for August 2025, presenting a significant growth opportunity for Veeva in the clinical trial technology sector [9][10] Market Position - Veeva currently holds a market capitalization of $37.69 billion and reported an earnings surprise of 10.1% in the last quarter [5] - The adoption of SiteVault CTMS could lead to increased recurring revenue from subscriptions, contributing to Veeva's long-term financial stability [10] - Veeva's strategic product launches and integrations reinforce its leadership in cloud-based solutions for the life sciences industry [11]

Core Insights - Veeva Systems has announced the launch of Veeva SiteVault CTMS, a clinical trial management system designed to enhance research site efficiency and integrate seamlessly with sponsors [1][2] - The system will be available for free to over 90% of research sites, specifically those managing up to 20 concurrent active studies, with an initial release planned for August 2025 [2] Group 1: Product Features and Benefits - Veeva SiteVault CTMS integrates with SiteVault eISF and SiteVault eConsent, allowing comprehensive management of clinical trials within a single system [1] - The integration with Veeva's Clinical Platform facilitates seamless bidirectional data flow between sites and sponsors, reducing manual processes and increasing efficiency [1][2] - The streamlined user experience provided by Veeva SiteVault is expected to enhance the speed of clinical trials, benefiting patients [2] Group 2: Company Commitment and Market Position - Veeva Systems is recognized as the global leader in cloud software for the life sciences industry, serving over 1,000 customers, including major biopharmaceutical companies and emerging biotechs [3] - As a Public Benefit Corporation, Veeva is dedicated to balancing the interests of all stakeholders, including customers, employees, and shareholders [3]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________________________________ FORM 10-K ____________________________________________________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended January 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the ...

Specialized CRO standardizes on Veeva RTSM to drive operational efficiency and faster study timelinesPLEASANTON, Calif., March 19, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Indero, formerly Innovaderm Research, successfully launched its 40th RTSM study on Veeva RTSM. By standardizing with Veeva RTSM, Indero has strengthened its clinical trial operations, harnessing advanced RTSM capabilities and expert support to drive efficiency, enhance process consistency, and streamline execut ...

I gave a buy rating to Veeva Systems (NYSE: VEEV ) in December, with my key thesis being that the business should see accelerating growth as the broader demand environment normalizes and as VEEV continues to haveI'm a passionate investor with a strong foundation in fundamental analysis and a keen eye for identifying undervalued companies with long-term growth potential. My investment approach is a blend of value investing principles and a focus on long-term growth. I believe in buying quality companies at a ...

Core Insights - Wall Street analysts' recommendations significantly influence investors' decisions regarding stock transactions, particularly for Veeva Systems (VEEV) [1][4] - Veeva currently holds an average brokerage recommendation (ABR) of 1.97, indicating a consensus between Strong Buy and Buy, based on 27 brokerage firms' recommendations [2][12] Brokerage Recommendations - The breakdown of the 27 recommendations includes 14 Strong Buy (51.9%) and 3 Buy (11.1%), reflecting a strong positive sentiment towards Veeva [2][12] - Despite the favorable ABR, reliance solely on brokerage recommendations may not yield the best investment outcomes, as studies indicate limited success in predicting stock price increases [4][9] Analyst Bias and Tools - Analysts from brokerage firms often exhibit a positive bias due to vested interests, leading to a higher number of favorable ratings compared to negative ones [5][9] - The Zacks Rank, a proprietary stock rating tool, is suggested as a more reliable indicator of stock performance, based on earnings estimate revisions rather than brokerage recommendations [7][10] Earnings Estimates and Future Outlook - The Zacks Consensus Estimate for Veeva has increased by 6.5% over the past month to $7.21, indicating growing optimism among analysts regarding the company's earnings prospects [12][13] - The recent change in consensus estimates, along with other factors, has resulted in a Zacks Rank 1 (Strong Buy) for Veeva, suggesting a potential for stock price appreciation [12][13]

Core Viewpoint - Veeva Systems (VEEV) has been upgraded to a Zacks Rank 1 (Strong Buy), indicating a positive outlook driven by rising earnings estimates, which significantly influence stock prices [1][2]. Earnings Estimates and Stock Price Impact - The Zacks rating system emphasizes the importance of changing earnings estimates, which are closely correlated with near-term stock price movements [3]. - Institutional investors rely on earnings estimates to determine the fair value of stocks, leading to significant buying or selling activity that affects stock prices [3]. Business Improvement Indicators - The upgrade in Veeva's rating reflects an improvement in the company's underlying business, suggesting that investor sentiment may drive the stock price higher [4]. Earnings Estimate Revisions - Veeva is projected to earn $7.21 per share for the fiscal year ending January 2026, representing a year-over-year increase of 9.2% [7]. - Over the past three months, the Zacks Consensus Estimate for Veeva has risen by 7.1%, indicating a positive trend in earnings expectations [7]. Zacks Rank System Overview - The Zacks Rank system categorizes stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [6]. - Only the top 5% of Zacks-covered stocks receive a 'Strong Buy' rating, highlighting their superior earnings estimate revision characteristics [8][9].

Top 20 biopharma goes live with Veeva Development Cloud to speed the delivery of treatments for currently incurable diseases INGELHEIM, Germany and BARCELONA, Spain, March 11, 2025 /PRNewswire/ -- Today, Boehringer Ingelheim and Veeva Systems (NYSE: VEEV) have announced the launch of Boehringer's One Medicine Platform, powered by the successful implementation of Veeva Development Cloud. They first announced the One Medicine collaboration in March 2022. The unified platform brings together data and processes ...

Company Overview - Veeva Systems Inc. announced Veeva CRM Pulse, a data subscription service providing quarterly healthcare professional access and multichannel engagement metrics for the life sciences industry [1] - The service is currently available for Veeva's CRM customers, covering 2024 quarterly data across multiple countries including the US, Canada, and several European and Asian nations [2] - The introduction of CRM Pulse is expected to significantly enhance the Veeva Data Cloud product category, thereby boosting overall business performance [3] Financial Performance - Following the announcement of CRM Pulse, Veeva's shares increased by nearly 7.9% [4] - The company has a market capitalization of $38.34 billion and an earnings yield of 2.9%, which is favorable compared to the industry's negative yield [5] - In the last reported quarter, Veeva delivered an earnings surprise of 10.1% [5] Strategic Significance - Management believes that CRM Pulse will improve global segmentation and targeting, enhancing the value of data for commercial operations [6] - The latest availability of healthcare professional access data is seen as a significant milestone for Veeva Systems, expected to boost its business [8] Industry Prospects - The global healthcare analytics market was valued at $43.1 billion in 2023 and is projected to grow at a CAGR of 21.1% from 2024 to 2030, driven by technological advancements and the need for improved patient care [7]

Shares of Veeva Systems (VEEV 9.60%) are posting big gains in Thursday's trading despite broader sell-offs for the tech sector. The life-sciences software company's stock was up 10.2% as of 12:30 p.m. ET today.Veeva Systems reported its fourth-quarter results after the market closed yesterday and posted better-than-expected sales and earnings results. The company's outlook also topped Wall Street's expectations.Veeva stock rises on a strong Q4Adjusted earnings per share (EPS) of $1.74 on sales of $720.89 mi ...